Here, they found that CD166 levels in primary NSCLC specimens are associated with smaller tumors without lymph node metastasis and had no prognostic effect on patient survival, thus indicating CD166 as an atypical CSC marker. The gene discussed is ALCAM; the disease is metastatic malignant neoplasm in the lymph nodes.